TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the Company has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for any investigators who intend to study…


Previous articleThe Missing Mushroom: Psychedelic Science and the Future of Psilocybin
Next articleComplete Results from Red Light Oregon Market Research in Oregon Show Microdosing Services Market Size per Annum Estimated at a Billion USD